Acorda Therapeutics, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
8
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 14, 2027The maintenance fee for Use of a neuregulin to treat peripheral nerve injury (US 9,078,861) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure (US 9,198,951) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Method for achieving desired glial growth factor 2 plasma levels (US 9,272,015) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Methods for detecting cardiac damage (US 9,329,171) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,485,295 | Compositions and methods of using chondroitinase ABCI mutants In force · USPTO record | In force | USPTO record | |
| US 8,007,826 | Sustained release aminopyridine composition In force · USPTO record | In force | USPTO record | |
| US 9,329,171 | Methods for detecting cardiac damage In force · USPTO record | In force | USPTO record | |
| US 10,258,667 | Methods for detecting cardiac damage In force · USPTO record | In force | USPTO record | |
| US 10,675,331 | Method for achieving desired glial growth factor 2 plasma levels In force · USPTO record | In force | USPTO record | |
| US 9,272,015 | Method for achieving desired glial growth factor 2 plasma levels In force · USPTO record | In force | USPTO record | |
| US 9,198,951 | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure In force · USPTO record | In force | USPTO record | |
| US 10,668,131 | Compositions and methods for treatment during non-acute periods following CNS neurological injury In force · USPTO record | In force | USPTO record | |
| US 9,078,861 | Use of a neuregulin to treat peripheral nerve injury In force (reinstated) · USPTO record | In force (reinstated) | USPTO record |
Also on record, not counted in the 9: 2 patents in force now held by others · 45 lapsed for an unpaid fee · 64 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 abandoned · 83 no status recorded